Olatorepatide
A weekly GLP-1/GIP dual agonist from Hansoh; its first phase 3 trial in China reported in October 2026, and Regeneron is testing it elsewhere.
Olatorepatide (HS-20094) is a weekly injection that activates the GLP-1 and GIP receptors, like tirzepatide; Hansoh reported its 604-person LIGHTEN phase 3 trial in China in October 2026, and Regeneron, which licensed it outside China, has registered the global phase 3 RISE-1.
No dosing data yet Details ↓
Recommended Dosing
No dosing data yet
This page has no dosing data yet.
Mechanism of action
Activates the GLP-1 and GIP receptors, the pair tirzepatide targets; Hansoh describes it as dual-biased. No paper on PubMed describes its pharmacology yet (searched October 30, 2026).
Primary uses
- Obesity and overweight (phase 3)
- Type 2 diabetes (clinical trials)
Typical dosing
No dose in a paper or label we can cite: no paper on olatorepatide was on PubMed on October 30, 2026. The three weekly doses LIGHTEN tested are named only in the company's release, so none is printed here.
Regulatory status
Not approved anywhere. Phase 3 LIGHTEN in 604 Chinese adults with overweight or obesity is complete (NCT06839664); Regeneron's phase 3 RISE-1 (NCT07896265, 3,000 participants planned) was not yet recruiting when read.
Status as of this entry's last review, October 30, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What the studies show
Olatorepatide has no paper on PubMed yet. What exists is the company's phase 3 announcement and the trial registrations below.
Registry · 2024
A Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects
LIGHTEN: 604 Chinese adults with overweight or obesity, completed January 2026. The company reported 11.8%, 17.0% and 18.7% weight loss on three doses against 2.5% on placebo at week 48 (treatment-regimen estimand); no peer-reviewed paper yet.
NCT06839664 · ClinicalTrials.gov record
Registry · 2026
A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)
RISE-1: Regeneron's 3,000-person global phase 3 in overweight or obesity without diabetes, registered to start in November 2026.
NCT07896265 · ClinicalTrials.gov record
References
- [manufacturer] Hansoh Pharma press release, October 2, 2026: phase 3 LIGHTEN data of olatorepatide presented at EASD. Reported weight change at week 48 of 11.8%, 17.0% and 18.7% on three doses against 2.5% on placebo, counting everyone randomised.
- [clinicaltrials] ClinicalTrials.gov NCT06839664: "A Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects" Jiangsu Hansoh Pharmaceutical Co., Ltd.. Phase 3, completed, November 2024 to January 2026 (primary completion), 604 participants. Registry record read October 28, 2026.
- [manufacturer] Regeneron Pharmaceuticals press release, June 2, 2025: in-licensing of HS-20094 from Hansoh Pharma for territories outside mainland China, Hong Kong and Macau.
- [clinicaltrials] ClinicalTrials.gov NCT07896265: "A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)" Regeneron Pharmaceuticals. Phase 3, not yet recruiting, November 2026 to December 2028 (primary completion), 3000 participants. Registry record read October 28, 2026.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.